Cytoskeleton involvement in lithium-induced SH-SY5Y neuritogenesis and the role of glycogen synthase kinase 3β

Aging Clinical and Experimental Research

Volumn 27, Issue 3, 2015, Pages 255-263

  Nciri, Riadh ^a,b   Boujbiha, Mohamed Ali ^b   Jbahi, Samira ^b   Allagui, Mohamed Salah ^a,b   Elfeki, Abdelfattah ^b   Vincent, Christian ^a   Croute, Françoise ^a  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b Laboratoire d'Ecophysiologie Animale   (Tunisia)

Author keywords

Cytoskeleton; GSK3; Lithium; Neuritogenesis

Indexed keywords

ALPHA TUBULIN; BETA CATENIN; CASEIN KINASE II; CYTOSKELETON PROTEIN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM; RECEPTOR FOR ACTIVATED C KINASE 1; THYMOSIN BETA10; GLYCOGEN SYNTHASE; GLYCOGEN SYNTHASE KINASE 3 BETA; LITHIUM DERIVATIVE; NEUROPROTECTIVE AGENT;

ARTICLE; CELL ADHESION; CELL STRUCTURE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GROWTH CONE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; NERVE CELL NETWORK; NERVE CELL PLASTICITY; NERVE FIBER GROWTH; NEURITE; NEUROFILAMENT; WESTERN BLOTTING; CELL CULTURE; CYTOSKELETON; DRUG EFFECTS; METABOLISM; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; TREATMENT OUTCOME;

CELLS, CULTURED; CYTOSKELETON; GLYCOGEN SYNTHASE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LITHIUM COMPOUNDS; NERVE DEGENERATION; NEURITES; NEUROGENESIS; NEURONAL PLASTICITY; NEUROPROTECTIVE AGENTS; TREATMENT OUTCOME;

EID: 84929173955     PISSN: 15940667     EISSN: 17208319     Source Type: Journal    
DOI: 10.1007/s40520-014-0290-3     Document Type: Article

References (47)

1. Beal MF (1995) Aging, energy, and oxidative stress in neurodegenerative disorders. Ann Neurol 38:357–366
2. Harman D (1998) Aging: phenomena and theories. Ann NY Acad Sci 854:1–7
3. Behl C (1999) Alzheimer’s disease and oxidative stress: implications for novel therapeutic approaches. Prog Neurobiol 57:301–323
4. Selkoe DJ (2001) Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 81:741–766
5. Annaert W, De Strooper B (2002) A cell biological perspective on Alzheimer’s disease. Annu Rev Cell Dev Biol 18:25–51
6. Riadh Nciri, Allagui Mohamed Salah, Bourogaa Ezzedine, Vincent Christian, Croute Françoise, Elfeki Abdelfattah (2011) Neuroprotective and neurotrophic effects of long term lithium treatment in mouse brain. Biometals 24:747–757
7. Quiroz JA, Machado-Vieira R, Zarate CA, Manji JHK (2010) Novel insights into lithium’s mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology 62:50–60
8. Italia J, Mukhopadhyaya R, Rajadhyaksha MS (2011) Differential display RT-PCR reveals genes associated with lithium-induced neuritogenesis in SK-N-MC cells. Cell Mol Neurobiol 31:1021–1026
9. Mora A, Gonzalez-Polo RA, Fuentes JM, Soler G, Centeno F (1999) Different mechanisms of protection against apoptosis by valproate and Li+. Eur J Biochem 266:886–891
10. Bauer M, Alda M, Priller J, Young LT (2003) International Group for the Study of Lithium Treated Patients (IGSLI). Implications of the neuroprotective effects of lithium for the treatment of bipolar and neurodegenerative disorders. Pharmacopsychiatry 36:250–254
11. Chuang DM (2004) Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases. Crit Rev Neurobiol 16:83–90
12. Jin N, Kovacs AD, Sui Z, Dewhurst S, Maggirwar SB (2005) Opposite effects of lithium and valproic acid on trophic factor deprivation-induced glycogen synthase kinase-3 activation, c-Jun expression and neuronal cell death. Neuropharmacology 48:576–583
13. Berridge MJ, Downes CP, Hanley MR (1989) Neural and developmental actions of lithium: a unifying hypothesis. Cell 59:411–419
14. Klein PS, Melton DA (1996) A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 93:8455–8459
15. Stambolic V, Ruel L, Woodgett JR (1996) Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 6:1664–1668
16. Phiel CJ, Klein PS (2001) Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 41:789–813
17. Grimes CA, Jope RS (2001) The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 65:391–426
18. Jope RS (2003) Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci 24:441–443
19. Sasaki T, Han F, Shioda N, Moriguchi S, Kasahara J, Ishiguro K, Fukunaga K (2006) Lithium-induced activation of Akt and CaM kinase II contributes to its neuroprotective action in a rat microsphere embolism model. Brain Res 1108:98–106
20. Liang MH, Wendland JR, Chuang DM (2008) Lithium inhibits Smad3/4 transactivation via increased CREB activity induced by enhanced PKA and AKT signaling. Mol Cell Neurosci 37:440–453
21. Bielecka AM, Obuchowicz E (2008) Antiapoptotic action of lithium and valproate. Pharmacol Rep 60:771–782
22. Marmol F (2008) Lithium: bipolar disorder and neurodegenerative diseases, possible cellular mechanisms of the therapeutic effects of lithium. Prog Neuropsychopharmacol Biol Psychiatry 32:1761–1771
23. Machado-Vieira R, Manji HK, Zarate CA (2009) The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord 11:92–109
24. Wada A (2009) Lithium and neuropsychiatric therapeutics: neuroplasticity via glycogen synthase kinase-3beta, beta-catenin, and neurotrophin cascades. J Pharmacol Sci 110:14–28
25. Lowry OH, Rosebrouch NJ, Farr AL, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265–275
26. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685
27. Jope RS (1999) Anti-bipolar therapy: mechanism of action of lithium. Mol Psych 4:117–128
28. Burgoyne RD (1991) High molecular weight microtubule-associated proteins of brain. In: Burgoyne RD (ed) The neuronal cytoskeleton. Wiley, New York, pp 75–91
29. Chen G, Manji HK (2006) The extracellular signal-regulated kinase pathway: an emerging promising target for mood stabilizers. Curr Opin Psychiatry 19:313–323
30. Garcia-Perez J, Avila J, Diaz-Nido J (1999) Lithium induces morphological differentiation of mouse neuroblastoma cells. J Neurosci Res 57:261–270
31. Muñoz-Montaño JR, Lim F, Moreno FJ, Avila J, Díaz-Nido J (1999) Glycogen synthase kinase-3 modulates neurite outgrowth in cultured neurons: possible implications for neurite pathology in Alzheimer’s disease. J Alzheimers Dis 1:361–378
32. Williams R, Ryves WJ, Dalton EC, Eickholt B, Shaltiel G, Agam G, Harwood AJ (2004) A molecular cell biology of lithium. Biochem Soc Trans 32:799–802
33. Fiona RL, Robert GG, Phillip RGW, Patricia CS (1998) Inhibition of GSK-3b leading to the loss of phosphorylated MAP-1B is an early event in axonal remodelling induced by WNT-7a or lithium. J Cell Sci 111:1351–1361
34. Yu FX, Lin SC, Morrison-Bogorad M, Atkinsonil MAL, Yin HL (1993) Thymosin β 10 and thymosin β 4 are both actin monomer sequestering proteins. J Biol Chem 268:502–509
35. Golla R, Philp N, Safer D, Chintapalli J, Hoffman R, Collins L, Nachmias VT (1997) Co-ordinate regulation of the cytoskeleton in 3T3 cells overexpressing thymosin-beta4. Cell Motil Cytoskeleton 38:187–200
36. Chakraborty A, Werner JK, Koldobskiy JMA, Mustafa AK, Juluri KR, Pietropaoli J, Snowman AM, Snyder SH (2011) Casein kinase-2 mediates cell survival through phosphorylation and degradation of inositol hexakisphosphate kinase-2. PNAS 108:2205–2209
37. Song DH, Dominguez I, Mizuno J, Kaut M, Mohr SC, Seldin DC (2003) CK2 phosphorylation of the armadillo repeat region of β catenin potentiates Wnt signaling. J Biol Chem 278:24018–24025
38. Ulloa L, Díaz-Nido J, Avila J (1993) Depletion of casein kinase II by antisense oligodeoxy-nucleotide prevents neuritogenesis in neuroblastoma cells. EMBO J 12:1633–1640
39. Nilsson J, Sengupta J, Frank J, Nissen P (2004) Regulation of eukaryotic translation by the RACK1 protein: a platform for signaling molecules on the ribosome. EMBO Rep 5:1137–1141
40. Jansen SR, Van Ziel AM, Baarsma HA, Gosens R (2010) β-Catenin regulates airway smooth muscle contraction. Am J Physiol Lung Cell Mol Physiol 299:204–214
41. Brembeck FH, Rosário M, Birchmeier W (2006) Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. Curr Opin Genet Dev 16:51–59
42. Hongisto V, Smeds N, Brecht S, Herdegen T, Courtney MJ, Coffey ET (2003) Lithium blocks the c-Jun stress response and protects neurons via its action on glycogen synthase kinase 3. Mol Cell Biol 23:6027–6036
43. Nciri R, Desmoulin F, Allagui MS, Murat JC, Feki AE, Vincent C, Croute F (2013) Neuroprotective effects of chronic exposure of SHSY5Y to low lithium concentration involve glycolysis stimulation, extracellular pyruvate accumulation and resistance to oxidative stress. Int J Neuropsychopharmacol 16:365–376
44. Nciri R, Bourogaa E, Jbahi S, Allagui MS, Elfeki A, Vincent C, Croute F (2014) Chronic neuroprotective effects of low concentration lithium on SH-SY5Y cells: possible involvement of stress proteins and gene expression. Neural Regen Res 9:735–740
45. Leng Y, Liang MH, Ren M, Marinova Z, Leeds P, Chuang DM (2008) Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J Neurosci 28:2576–2588
46. Rowe MK, Wiest C, Chuang DM (2007) GSK-3 is a viable potentia l target for therapeutic intervention in bipolar disorder. Neurosci Biobehav Rev 31:920–931
47. Orme MH, Giannini AL, Vivanco MD, Kypta RM (2003) Glycogen synthase kinase-3 and Axin functionin a βcatenin-independent pathway that regulates neurite outgrowth in neuroblastoma cells. Mol Cell Neurosci 24:673–686